Users online: 2494    [ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2016, Volume : 9, Issue : 5
First page : ( 562) Last page : ( 570)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2016.00107.4

Melanoma and its Drug Targets

Ojaswi Ghadge1,2,*, Divya Nadar1, Digna Parmar1

1H. K. College of Pharmacy, Near Oshiwara, Jogeshwari (W)-400 102

2C. U. Shah College of Pharmacy, Juhu Tara Road, Santacruz (W)-400 049

*Corresponding Author E-mail: ojaswi.phalke@hkcollege.ac.in, ojaswi.ghadge@gmail.com; ojaswi.phalke@hkcp.edu.in

Online published on 21 June, 2016.


Melanoma is the most lethal type among skin cancers, causing about 75% of all skin cancer deaths. Melanoma patients have different responses to therapy, depending on what genes are mutated on their tumours. About half of melanomas have a mutation in the BRAF gene; while a quarter have a mutation in the genes of RAS family (NRAS, HRAS, KRAS). New BRAF inhibitors are effective against BRAF mutant melanoma, but no comparable therapies are currently available against RAS mutant melanoma. Inhibition of MEK (Mitogen Activated Protein Kinase Kinase, it is encoded by Extracellular Signal Regulated Kinase gene), a downstream protein within the Mitogen-Activated Protein Kinase (MAPK) pathway, can induce apoptosis. Inhibition of the MAPK signaling at any level can assist in the treatment of melanoma.



Melanoma, Skin cancer, BRAF, NRAS, MEK, MAPK (Mitogen Activated Protein Kinase) pathway.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
446,236,064 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.